For PAAD patients, high expression of DLAT significantly enhances resistance to these agents, which include AZD2014 (vistusertib), pictilisib, dactolisib, etc. This phenomenon is consistent with the results of functional enrichment analysis in which the PI3K/Akt and MAPK pathways were enriched in DLAT-high samples. The gene discussed is AKT1; the disease is pancreatic adenocarcinoma.